304.01

0.89% -2.6466

Alnylam Pharmaceuticals Inc (ALNY)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt ALNY? Forum Prognose

Schlusskurs vom Vortag:

$306.66

Offen:

$303.42

24-Stunden-Volumen:

623.77K

Relative Volume:

0.42

Marktkapitalisierung:

$40.32B

Einnahmen:

$3.71B

Nettoeinkommen (Verlust:

$313.75M

KGV:

134.69

EPS:

2.2571

Netto-Cashflow:

$465.38M

1W Leistung:

-5.14%

1M Leistung:

-8.69%

6M Leistung:

-33.69%

1J Leistung:

+4.55%

1-Tages-Spanne:

$299.62

$305.97

1-Wochen-Bereich:

$299.62

$323.23

52-Wochen-Spanne:

$205.87

$495.55

Alnylam Pharmaceuticals Inc Stock (ALNY) Company Profile

Firmenname

Alnylam Pharmaceuticals Inc

Sektor

Healthcare (1114)

Branche

Biotechnology (621)

Telefon

(617) 551-8200

Adresse

675 WEST KENDALL STREET, CAMBRIDGE, MA

Mitarbeiter

2,500

Twitter

@alnylam

Nächster Verdiensttermin

2026-02-12

Neueste SEC-Einreichungen

ALNY's Discussions on Twitter

Compare ALNY vs VRTX, REGN, ARGX, INSM

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
ALNY Alnylam Pharmaceuticals Inc	304.03	40.67B	3.71B	313.75M	465.38M	2.2571
VRTX Vertex Pharmaceuticals Inc	450.38	114.63B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	736.74	77.87B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	676.84	42.32B	4.16B	1.29B	734.26M	19.58
INSM Insmed Inc	140.56	31.04B	606.42M	-1.28B	-997.58M	-6.403

Alnylam Pharmaceuticals Inc Stock (ALNY) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2026-03-16	Herabstufung	Jefferies	Buy → Hold
2026-01-28	Fortgesetzt	Barclays	Overweight
2026-01-07	Fortgesetzt	Oppenheimer	Outperform
2025-08-04	Hochstufung	Oppenheimer	Perform → Outperform
2025-08-04	Hochstufung	Wolfe Research	Underperform → Peer Perform
2025-07-30	Fortgesetzt	Raymond James	Outperform
2025-07-21	Eingeleitet	Truist	Buy
2025-03-31	Eingeleitet	Redburn Atlantic	Buy
2025-03-24	Hochstufung	JP Morgan	Neutral → Overweight
2024-11-12	Herabstufung	Wolfe Research	Peer Perform → Underperform
2024-10-16	Eingeleitet	Scotiabank	Sector Outperform
2024-08-16	Hochstufung	Goldman	Neutral → Buy
2024-02-16	Herabstufung	Goldman	Buy → Neutral
2024-02-15	Eingeleitet	Wolfe Research	Peer Perform
2023-12-08	Eingeleitet	Wells Fargo	Equal Weight
2023-10-11	Herabstufung	Oppenheimer	Outperform → Perform
2023-09-29	Eingeleitet	Raymond James	Outperform
2023-05-05	Hochstufung	BMO Capital Markets	Market Perform → Outperform
2023-04-26	Eingeleitet	SMBC Nikko	Neutral
2023-03-21	Eingeleitet	Bernstein	Outperform
2023-01-18	Eingeleitet	Canaccord Genuity	Buy
2022-09-09	Fortgesetzt	Morgan Stanley	Equal-Weight
2022-07-13	Eingeleitet	Cantor Fitzgerald	Neutral
2022-06-27	Herabstufung	Guggenheim	Buy → Neutral
2022-06-07	Eingeleitet	William Blair	Outperform
2022-04-25	Herabstufung	Morgan Stanley	Overweight → Equal-Weight
2022-03-01	Eingeleitet	Citigroup	Buy
2022-02-03	Hochstufung	Guggenheim	Neutral → Buy
2022-01-03	Hochstufung	Piper Sandler	Neutral → Overweight
2021-11-22	Hochstufung	Goldman	Neutral → Buy
2021-11-22	Hochstufung	RBC Capital Mkts	Sector Perform → Outperform
2021-11-01	Hochstufung	Oppenheimer	Perform → Outperform
2021-10-04	Hochstufung	UBS	Neutral → Buy
2021-08-04	Herabstufung	Piper Sandler	Overweight → Neutral
2021-02-22	Herabstufung	Guggenheim	Buy → Neutral
2021-02-12	Herabstufung	Citigroup	Buy → Neutral
2021-02-12	Bestätigt	H.C. Wainwright	Buy
2021-01-25	Herabstufung	BMO Capital Markets	Outperform → Market Perform
2020-09-30	Fortgesetzt	Berenberg	Hold
2020-09-08	Eingeleitet	Citigroup	Buy
2020-08-11	Herabstufung	Oppenheimer	Outperform → Perform
2020-05-13	Eingeleitet	RBC Capital Mkts	Sector Perform
2020-05-07	Herabstufung	JP Morgan	Overweight → Neutral
2020-04-24	Fortgesetzt	Evercore ISI	Outperform
2020-03-19	Eingeleitet	Berenberg	Buy
2019-12-19	Bestätigt	Chardan Capital Markets	Buy
2019-11-20	Eingeleitet	Oppenheimer	Outperform
2019-11-13	Eingeleitet	BofA/Merrill	Buy
2019-05-23	Fortgesetzt	Goldman	Neutral
2019-04-12	Eingeleitet	Evercore ISI	Outperform
2019-03-06	Hochstufung	Evercore ISI	In-line → Outperform
2019-03-05	Hochstufung	Morgan Stanley	Equal-Weight → Overweight
2019-01-23	Eingeleitet	UBS	Neutral
2018-10-01	Eingeleitet	Cantor Fitzgerald	Overweight
2018-08-13	Bestätigt	Stifel	Buy
2018-08-07	Hochstufung	Stifel	Hold → Buy
2018-05-04	Bestätigt	Stifel	Hold
2018-03-28	Eingeleitet	Evercore ISI	In-line

Alle ansehen

Alnylam Pharmaceuticals Inc Aktie (ALNY) Neueste Nachrichten

09:00 AM

Viz.ai Partners with Alnylam Pharmaceuticals to Advance Earlier Identification and Care Coordination in Cardiac Amyloidosis - Business Wire

09:00 AM

07:30 AM

Alnylam backs AI screening and a 10-site effort for missed heart disease - Stock Titan

07:30 AM

04:42 AM

Congress Asset Management Co. Boosts Position in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat

04:42 AM

Mar 22, 2026

Hudson Bay Capital Management LP Lowers Holdings in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat

Mar 22, 2026

Mar 21, 2026

Chart Watch: Does Alnylam Pharmaceuticals Inc have a sustainable dividend2026 EndofYear Setup & Weekly High Return Forecasts - baoquankhu1.vn

Mar 21, 2026

Growth Review: What analysts say about Alnylam Pharmaceuticals Inc stockQuarterly Performance Summary & High Accuracy Investment Entry Signals - baoquankhu1.vn

Mar 21, 2026

Alnylam’s research pact worth up to $1.1B sends Tenaya higher - MSN

Mar 21, 2026

Alnylam Pharmaceuticals (ALNY) reports $3B 2025 revenue driven by 151% TTR franchise surge - MSN

Mar 21, 2026

Alnylam Pharmaceuticals (NASDAQ:ALNY) Downgraded by Wall Street Zen to "Hold" - MarketBeat

Mar 21, 2026

Mar 20, 2026

Polar Asset Management Partners Inc. Reduces Holdings in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat

Mar 20, 2026

Alnylam and Tekmira Restructure Relationship and Settle All Litigation - Yahoo

Mar 20, 2026

Mar 19, 2026

Alnylam’s Cardiovascular RNAi Collaboration With Tenaya Might Change The Case For Investing In ALNY - Sahm

Mar 19, 2026

Can Alnylam's Pipeline Medications Drive Sustainable Growth in the Future? - Bitget

Mar 19, 2026

Can Alnylam's Pipeline Drugs Sustain Long-Term Growth Ahead? - The Globe and Mail

Mar 19, 2026

Novartis acquisition spin-off pioneers RNA therapeutics for the heart - Pharma Voice

Mar 19, 2026

Groupama Asset Managment Purchases 2,483,697 Shares of Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat

Mar 19, 2026

CIBC Private Wealth Group LLC Reduces Position in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat

Mar 19, 2026

1ALNY.MI Income Statement | ALNYLAM PHARMACEUTICALS INC (BIT:1ALNY) - ChartMill

Mar 19, 2026

Mar 18, 2026

Canaccord Genuity maintains buy rating on Alnylam Pharmaceuticals, Inc. (ALNY) stock - MSN

Mar 18, 2026

Mar 17, 2026

Alnylam Pharmaceuticals Q2 2025 Earnings Preview - MSN

Mar 17, 2026

Here's How Much You Would Have Made Owning Alnylam Pharmaceuticals Stock In The Last 20 Years - Benzinga

Mar 17, 2026

The $3B Biotech With Two Shots On Goal - Benzinga

Mar 17, 2026

Linden Advisors LP Makes New $6.55 Million Investment in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat

Mar 17, 2026

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Short Interest Down 12.8% in February - MarketBeat

Mar 17, 2026

Brevan Howard Capital Management LP Buys Shares of 6,170 Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat

Mar 17, 2026

Jefferies downgrades Alnylam Pharmaceuticals (ALNY) - MSN

Mar 17, 2026

California Public Employees Retirement System Buys 18,060 Shares of Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat

Mar 17, 2026

Bamco Inc. NY Acquires New Shares in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat

Mar 17, 2026

(ALNY) and the Role of Price-Sensitive Allocations - Stock Traders Daily

Mar 17, 2026

A Look At Alnylam Pharmaceuticals (ALNY) Valuation After New Tenaya Cardiovascular Partnership - simplywall.st

Mar 17, 2026

Mar 16, 2026

JP Morgan Maintains Alnylam Pharmaceuticals (ALNY) Overweight Recommendation - MSN

Mar 16, 2026

ALNY Downgraded by Jefferies with Price Target Significantly Low - GuruFocus

Mar 16, 2026

Alnylam Pharmaceuticals (NASDAQ:ALNY) Earns Hold Rating from Jefferies Financial Group - MarketBeat

Mar 16, 2026

Jain Global LLC Purchases 61,316 Shares of Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat

Mar 16, 2026

Here Are Monday’s Top Wall Street Analyst Research Calls: Alnylam Pharmaceuticals, Circle Internet, Fifth Third Bancorp, Intuit, ServiceNow, Qualcomm, Trade Desk, and More - Yahoo Finance

Mar 16, 2026

Patisiran Comprehensive Forecast on the Accelerating Market - openPR.com

Mar 16, 2026

Mar 15, 2026

6,888 Shares in Alnylam Pharmaceuticals, Inc. $ALNY Acquired by Capula Management Ltd - MarketBeat

Mar 15, 2026